Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer

Hwee‐Yong ‐Y Yap; George R. Blumenschein; Charles K. Tashima; Gabriel N. Hortobagyi; Aman U. Buzdar; Charles L. Wiseman

doi:10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3

Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer

Hwee‐Yong ‐Y Yap
, George R. Blumenschein
, Charles K. Tashima
, Gabriel N. Hortobagyi
, Aman U. Buzdar
, Charles L. Wiseman

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m² iv and vincristine 1.5 mg/m² iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.

Original language	English (US)
Pages (from-to)	32-34
Number of pages	3
Journal	Cancer
Volume	44
Issue number	1
DOIs	https://doi.org/10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3
State	Published - Jul 1979

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3

Cite this

@article{73ab3d58a4cd40b4b748ab600c47d79c,

title = "Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer",

abstract = "Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23\%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41\%) the disease remained stable. Toxicity was minimal.",

author = "Yap, \{Hwee‐Yong ‐Y\} and Blumenschein, \{George R.\} and Tashima, \{Charles K.\} and Hortobagyi, \{Gabriel N.\} and Buzdar, \{Aman U.\} and Wiseman, \{Charles L.\}",

year = "1979",

month = jul,

doi = "10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3",

language = "English (US)",

volume = "44",

pages = "32--34",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer

AU - Yap, Hwee‐Yong ‐Y

AU - Blumenschein, George R.

AU - Tashima, Charles K.

AU - Hortobagyi, Gabriel N.

AU - Buzdar, Aman U.

AU - Wiseman, Charles L.

PY - 1979/7

Y1 - 1979/7

N2 - Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.

AB - Eighteen patients with advanced breast cancer refractory to combination chemotherapy with 5‐FU, Adriamycin, Cytoxan (FAC) were treated with methotrexate 30 to 40 mg/m2 iv and vincristine 1.5 mg/m2 iv at weekly intervals. Of 17 evaluable patients, 4 (23%) achieved a partial remission with a median duration of remission of 6 months and a median survival of 10 months. In another seven of seventeen patients (41%) the disease remained stable. Toxicity was minimal.

UR - https://www.scopus.com/pages/publications/0018764993

UR - https://www.scopus.com/pages/publications/0018764993#tab=citedBy

U2 - 10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3

DO - 10.1002/1097-0142(197907)44:1<32::AID-CNCR2820440106>3.0.CO;2-3

M3 - Article

C2 - 222433

AN - SCOPUS:0018764993

SN - 0008-543X

VL - 44

SP - 32

EP - 34

JO - Cancer

JF - Cancer

IS - 1

ER -

Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this